Chinese regulators gave their nod to the second domestic CAR-T cell therapy in three months, raising concerns in the market about how companies will make these expensive, advanced treatments more accessible to Chinese patients. The PD-1 frenzy also continued with PD-1 biosimilars.
Latest Articles
Elise Mak
·
2 hours ago
Sinotau Pharmaceutical Group said it closed a Series D+ round to raise RMB320 million ($50 million) to support clinical research and development of radiopharmaceuticals, and more news from Luoxin Pharmaceutical, Zai Lab and Antengene.
News
Danni Yin
·
6 hours ago
Chinese regulators gave their nod to the second domestic CAR-T cell therapy in three months, raising concerns in the market about how companies will make these expensive, advanced treatments more accessible to Chinese patients. The PD-1 frenzy also continued with PD-1 biosimilars.
China Deals Tracker
Minhua Chu
·
Yesterday
Why was the approval decision so controversial? Has the FDA lowered its normal standards during the review? Wang clarified the questions about the review with data from the published FDA reports.
Feature
Elise Mak
·
Yesterday
After publishing preclinical data of EEDi-5273 in the Journal of Medicinal Chemistry, Ascentage Pharma hopes to move what it believes to be a best-in-class drug to the clinic soon, and more news from Huadong Medicine, Huashen Intelligent Pharma and Lianbio.
News
Elise Mak
·
2 days ago
With its HIFI screening technology, Berry Oncology has developed one single test to early screen for liver, lung, gastric, colorectal, esophageal and pancreatic cancers. Results unveiled at IBIWS last week showed an overall sensitivity of 87.6%, specificity of 99.1% and overall Tissue of Origin precision in 82% of positive cancers.
Feature
Elise Mak
·
2 days ago
The NMPA has approved Chipscreen Biosciences's chiglitazar as a treatment for type 2 diabetes, and more news from Legend Biotech and CTTQ.
News
Elise Mak
·
3 days ago
WuXi Advanced Therapies (WuXi ATU), a WuXi AppTec subsidiary focused on cell and gene therapy, said its new process development and commercial manufacturing facility opened in Shanghai, and more news from Bio-Thera Solutions, Huahui Health and Innovent.
News
Elise Mak
·
4 days ago
In an ongoing dispute surrounding Abraxane (paclitaxel), a drug that BeiGene licensed from BMS' subsidiary Celgene in 2017, the Chinese drugmaker said it intends to contest "vigorously" the termination proposed by its partner, and more news from GV20 Oncotherapy, HANSOH Pharma, Hengrui Pharma and Anticancer Bioscience.
News
Elise Mak
·
6 days ago
Takeda's Takecab (vonoprazan), an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved for a new indication in China, and more news from Boan Biotech and Eubulus Biotherapeutics.
News
PharmaDJ
·
7 days ago
Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers.
China Deals Tracker